SFA Therapeutics
Manufacturing · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
610 Old York Rd Ste 400, Jenkintown, Pen...Website
www.sfatherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About SFA Therapeutics
SFA Therapeutics, Inc. is a bio-pharmaceutical company focused on new human-microbiome-based advancements in the treatment of inflammatory diseases, targeting NF-kB and RAS. Chronic inflammation has been implicated in a wide range of diseases, including HCC, Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease (IBD), Crohn's Disease, Liver Disease and relapse/recurrence in AML and CML. SFA currently has five drugs under development, and is targeting Psoriasis, Hepatitis B and Hepatocellular Carcinoma (liver cancer) with their lead assets. SFA's small-molecule drugs are derived from natural substances produced in the human microbiome and enable a new platform for developing safer treatments for inflammatory diseases.Explore more
SFA Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SFA Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when SFA Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Click to see if SFA Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on SFA Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once SFA Therapeutics has new funding data
SFA Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if SFA Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at SFA Therapeutics
Check out if SFA Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined SFA Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to SFA Therapeutics
Compare insights from companies similar to SFA Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
SFA Therapeutics
<$5M
1-10
Private
<$5M
2017
JK
James KirwinChief Operating Officer & Senior VP, Clinical Development
Company Profile Activity
Activity Insights
SFA Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SFA Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SFA Therapeutics.
SFA Therapeutics financials insights
Gather financial insights about SFA Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Angel/Seed
$4M
SFA Therapeutics Tech Stack
A closer look at the technologies used by SFA Therapeutics
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Person-Based
Person-Based
SFA Therapeutics News & Media
Inside Philadelphia’s startup surge: 16 ventures to watch right now
Meet some of the companies growing Philly's reputation as a world-class innovation ecosystem.SFA Therapeutics Announces Positive Phase 1b Data of SFA-002 in Mild-to-Moderate Psoriasis
Subjects demonstrated statistically significant improvements in Psoriasis Area and Severity Index (PASI) and Investigator Global Assessment (IGA) scores JENKINTOWN, Pa., March 7, 2025 /PRNewswire/ -- SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oral...Head-to-Head Preclinical Studies of SFA-002 as a Novel Psoriasis Treatment Presented at the 2025 American Academy of Dermatology Annual Meeting
Mice dosed with SFA-002 displayed reduction in psoriasis disease severity and greater reduction in skin thickening compared to etanercept and apremilast in the in vivo model SFA-002 reduced key inflammatory markers and skin damage at comparable levels to betamethasone and apremilast in...SFA Therapeutics Appoints Dr. Ananda Gubbi as Director of Biostatistics
JENKINTOWN, Pa., Sept. 4, 2024 /PRNewswire/ -- SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for the treatment of inflammatory diseases, today announced the appointment of Dr. Ananda Gubbi, Ph.D., as Director of...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SFA Therapeutics
Sign Up For FreeTo access detailed company insights
SFA Therapeutics, Inc. is a bio-pharmaceutical company focused on new human-microbiome-based advancements in the treatment of inflammatory diseases, targeting NF-kB and RAS. Chronic inflammation has been implicated in a wide range of diseases, including HCC, Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease (IBD), C... Read More
